Abstract
The pathophysiology of multiple sclerosis (MS) is typically characterised by inflammation and demyelination leading to neurodegeneration, which is associated with disability and the progressive stages of MS. The visual system is a valuable tool for studying neurodegeneration and potential neuroprotection in the central nervous system due to its ease of accessibility. Optical coherence tomography (OCT) is a non-invasive tool, which can be used to measure the thickness of the retinal nerve fibre layer (RNFL). The thickness of RNFL is reduced following the development of MS and optic neuritis and can therefore be used as a correlate of global axonal loss. OCT is currently being investigated as a structural outcome measure for neuroprotective clinical trials of MS. This review describes the relationship between MS and optic neuritis and the associated RNFL thinning, the technology and advancements of OCT, the role of OCT in clinical trials for new neuroprotective therapies in MS and the future role of OCT in MS research.
Keywords: Multiple sclerosis, neuroprotection, optical coherence tomography, optic neuritis, retinal nerve fibre layer.
CNS & Neurological Disorders - Drug Targets
Title:Optical Coherence Tomography Detection of Neurodegeneration in Multiple Sclerosis
Volume: 11 Issue: 5
Author(s): Katie Lidster and David Baker
Affiliation:
Keywords: Multiple sclerosis, neuroprotection, optical coherence tomography, optic neuritis, retinal nerve fibre layer.
Abstract: The pathophysiology of multiple sclerosis (MS) is typically characterised by inflammation and demyelination leading to neurodegeneration, which is associated with disability and the progressive stages of MS. The visual system is a valuable tool for studying neurodegeneration and potential neuroprotection in the central nervous system due to its ease of accessibility. Optical coherence tomography (OCT) is a non-invasive tool, which can be used to measure the thickness of the retinal nerve fibre layer (RNFL). The thickness of RNFL is reduced following the development of MS and optic neuritis and can therefore be used as a correlate of global axonal loss. OCT is currently being investigated as a structural outcome measure for neuroprotective clinical trials of MS. This review describes the relationship between MS and optic neuritis and the associated RNFL thinning, the technology and advancements of OCT, the role of OCT in clinical trials for new neuroprotective therapies in MS and the future role of OCT in MS research.
Export Options
About this article
Cite this article as:
Lidster Katie and Baker David, Optical Coherence Tomography Detection of Neurodegeneration in Multiple Sclerosis, CNS & Neurological Disorders - Drug Targets 2012; 11 (5) . https://dx.doi.org/10.2174/187152712801661185
DOI https://dx.doi.org/10.2174/187152712801661185 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Current Pharmaceutical Design Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Metabolic Fate of Endocannabinoids
Current Neuropharmacology Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets The Role of Autophagy in Rheumatic Disease
Current Drug Targets Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges
Current Immunology Reviews (Discontinued) Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Use of Chemokines
Current Pharmaceutical Design VIP in Inflammatory Bowel Disease: State of the Art
Endocrine, Metabolic & Immune Disorders - Drug Targets